

AMENDMENTS TO THE CLAIMS

The following listing of claims replaces all prior versions of claims in the application.

1. (Currently Amended) A method for treatment of ~~kidney diseases~~ rapidly progressive glomerulonephritis syndrome or crescentic (extratubular) glomerulonephritis which comprises administering a composition for treatment of ~~kidney diseases~~ rapidly progressive glomerulonephritis syndrome or crescentic (extratubular) glomerulonephritis containing a PAR-2 activating agent as an effective ingredient to a patient suffering from ~~kidney diseases~~ rapidly progressive glomerulonephritis syndrome or crescentic (extratubular) glomerulonephritis.

2-4. (Cancelled)

5. (Previously Presented) The method according to claim 1, wherein the activator for PAR-2 is a PAR-2 ligand, a PAR-2 ligand derivative, trypsin, tryptase, tissue factor/VIIa factor, Xa factor, acrosin or a trypsin-like serine protease.

6. (Cancelled)